Article Details
Retrieved on: 2024-08-21 18:31:19
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses bipartisan US lawmakers urging greater scrutiny of clinical trials by American biotech firms in China, particularly in Xinjiang, citing concerns about intellectual property theft and forced Uyghur participation. This aligns with tags on human rights abuses and strategic competition.
Article found on: www.tbsnews.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here